SXLV:LSE:LSE-SPDR S&P U.S. Health Care Select Sector UCITS (USD)

ETF | Others |

Last Closing

USD 44.6488

Change

+0.06 (+0.14)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-19 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNIF:LSE Xtrackers Nifty 50 Swap UCITS ..

+162.50 (+0.83%)

USD 292,109.69B
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+2.20 (+0.87%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

+2.25 (+1.17%)

USD 1,607.29B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.08 (+0.41%)

USD 701.81B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.10 (+0.66%)

USD 636.56B
0R1I:LSE NVIDIA Corp.

-0.53 (-0.45%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.95 (-1.36%)

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

+0.18 (+0.57%)

USD 260.39B
0QZO:LSE 0QZO

+1.30 (+1.31%)

USD 258.54B

ETFs Containing SXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.52% 78% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.52% 77% C+ 71% C-
Trailing 12 Months  
Capital Gain 2.14% 37% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.14% 30% F 41% F
Trailing 5 Years  
Capital Gain 94.09% 64% D 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.09% 61% D- 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 10.51% 62% D 67% D+
Dividend Return 10.51% 61% D- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.62% 65% D 80% B-
Risk Adjusted Return 98.93% 87% B+ 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike